Renalytix Plc (RNLXY)

Market Cap	13.65M -64.7%
Revenue (ttm)	3.30M +35.1%
Net Income	-19.90M
EPS	-0.05
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	124
Average Volume	2,990
Open	1.700
Previous Close	1.610
Day's Range	1.700 - 1.700
52-Week Range	1.600 - 8.090
Beta	1.80
RSI	27.55
Earnings Date	Apr 1, 2026

About Renalytix

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management of kidney diseases in Europe and the United States. It offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. The company’s products are used in kidney disease diagnosis and prognosis, cl...

• Industry: Prepackaged Software
• Founded: 2018
• Employees: 46
• Stock Exchange: OTCMKTS
• Ticker Symbol: RNLXY

Financial Performance

In fiscal year 2025, Renalytix's revenue was $3.00 million, an increase of 30.43% compared to the previous year's $2.30 million. Losses were -$20.40 million, -55.16% less than in 2024.